Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cycrimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 8/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.97 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.97 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trihexyphenidyl SCHEMBL30061697 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Procyclidine SCHEMBL121684 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL5502902 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL42410 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL1320615 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Procyclidine SCHEMBL147344 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34646 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Cycrimine SCHEMBL249004 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34645 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| (S)-Procyclidine SCHEMBL519431 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073025-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4344552-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20210346385-A1 | TASTE-MASKED DOSAGE FORMS | DEEP OCEAN CAPITAL MANAGEMENT LP | 2021-11-11 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2020112814-A1 | DEVICES, SYSTEMS, AND METHODS TO MONITOR SUBJECT COMPLIANCE WITH A PHARMACEUTICAL TREATMENT REGIMEN | SAKAYA JAQUELINE MBWILLE (US) | 2020-06-04 | — | — | WO | disclosed |
| EP-0055043-B1 | 6,7,8,9-TETRAHYDRO-3H-BENZ(E)INDOLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND INTERMEDIATES USED THEREIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE INDOLAMINE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-01-23 | — | — | EP | disclosed |
| EP-0034894-B1 | 2-(1-PIPERAZINYL)-2,4,6-CYCLOHEPTATRIEN-1-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES USED IN THE PROCESSES AND THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-09-12 | — | — | EP | disclosed |
| US-4470990-A | 6,7,8,9-Tetrahydronaphtho(1,2-B)furan-8-amine derivatives and their use as dopamine receptor stimulants | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-09-11 | — | — | US | disclosed |
| US-4469695-A | 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON, INC. (CA) | 1984-09-04 | — | — | US | disclosed |
| US-4469693-A | 2-(4-Substituted alkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-09-04 | — | — | US | disclosed |
| US-4469694-A | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-09-04 | — | — | US | disclosed |
| US-4454150-A | 6,7,8,9-Tetrahydro-3H-benz(e)indol-7-amines and a method of dopamine receptor stimulation therewith | AYERST, MCKENNA & HARRISON INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4370341-A | 6,7,8,9-Tetrahydro-3H-benz[E]indol-8-amine derivatives | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1983-01-25 | — | — | US | disclosed |
| EP-0055043-A2 | 6,7,8,9-Tetrahydro-3H-benz(e)indolamine derivatives, processes for their preparation and intermediates used therein, and pharmaceutical compositions containing the indolamine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-06-30 | — | — | EP | disclosed |
| EP-0034894-A2 | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | CHRM1 2690/4885CHRM2 2576/4885CHRM3 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.